Top Tweets for #EVOLVEpro
Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning
1.This review outlines how high-throughput experimentation combined with machine learning (ML) is revolutionizing antibody discovery, enabling rapid identification and optimization of therapeutic candidates with enhanced affinity, specificity, and developability.
2.It highlights the importance of large, diverse datasets—comprising antibody sequences, structures, and experimental properties—which power ML models and reduce reliance on traditional trial-and-error screening.
3.Next-generation sequencing (NGS), phage/yeast/mammalian display, and advanced binding assays (e.g., BLI, SPR, DSF) are now used to rapidly acquire experimental data at scale, generating training sets for ML-guided design.
4.The review emphasizes the growing use of protein language models (PLMs)—including ESM-1b/2/3, AntiBERTy, and IgT5—that embed rich sequence-context relationships and can predict antibody affinity, stability, expression, and manufacturability.
5.Structural featurization via graph neural networks and models like ESM-3 further enhances predictions by incorporating 3D residue-residue context, critical for accurate function modeling.
6.Notable ML-guided affinity maturation examples include models that improved binding to HER2, PD-L1, and SARS-CoV-2 targets, achieving up to 37× affinity gains and complete preservation of target specificity.
7.Beyond affinity, data-driven methods have been applied to optimize thermostability (via TEMPRO), minimize viscosity (via DeepSCM), and improve developability by reducing aggregation and off-target binding.
8.Practical studies demonstrate how ML predictions trained on phage or yeast display data enable rapid identification of optimal antibody variants, even with few experimental rounds (e.g., EVOLVEpro's few-shot active learning strategy).
9.The review stresses that emerging PLMs like ESM-IF1 and diffusion-based models (e.g., RFdiffusion, AlphaProteo) enable structure-informed generative design, unlocking de novo creation of antibodies with programmable properties.
10.However, challenges remain: including modeling conformational epitopes, achieving multi-property optimization (e.g., affinity plus immunogenicity), and ensuring open-access data availability in a field dominated by industry players.
11.Looking ahead, the authors advocate for the development of open, interpretable AI models and collaborative experimental–computational pipelines to sustainably accelerate therapeutic antibody innovation.
📜Paper: jbiomedsci.biomedcentral.com… #AntibodyEngineering #MachineLearning #HighThroughput #PLMs #DrugDiscovery #TherapeuticAntibodies #Bioinformatics #AntibodyDesign #AIinBiotech

Another major breakthrough in AI-assisted protein engineering! This is highly significant, as it enables the rapid design & evolution of protein activity using few-shot active learning. EVOLVEpro is achieving up to 100-fold improvements in protein properties and functions! 🤯
EVOLVEpro, our general AI model for protein engineering, is now out in Science!
We show the ability to design and evolve dozens of unique proteins to have up to 500 times more activity or function using a combination of LLMs and regression models. 🧵👇
science.org/doi/10.1126/scie…
Rapid in silico directed evolution by a protein language model with EVOLVEpro @ScienceMagazine
• A breakthrough in protein engineering, EVOLVEpro combines protein language models (PLMs) with active learning to deliver up to 100-fold improvements in protein properties with minimal experimental data.
• EVOLVEpro surpasses conventional methods by using a few-shot learning framework, requiring only small mutant libraries to optimize diverse proteins, including CRISPR nucleases, antibodies, and RNA polymerases.
• The model efficiently navigates rugged fitness landscapes, avoiding local optima that plague traditional directed evolution approaches. It achieves this by integrating a PLM with a regression layer that learns protein activity landscapes.
• In antibody engineering, EVOLVEpro demonstrated multi-objective optimization, enhancing binding affinity and expression levels simultaneously—showcasing its potential in therapeutic antibody design.
• A highlight is the evolution of PsaCas12f, a compact CRISPR nuclease, achieving 50% editing efficiency at mammalian genomic loci, outperforming state-of-the-art miniature nucleases.
• EVOLVEpro-enabled engineering of T7 RNA polymerase (RNAP) yielded mutants that increased RNA production fidelity and reduced immunogenic byproducts, advancing RNA therapeutic applications.
• Structural analysis of mutations proposed by EVOLVEpro reveals novel insights, guiding future protein engineering strategies and demonstrating the power of combining computational predictions with experimental validation.
• The study benchmarks EVOLVEpro across 12 datasets, validating its broad applicability and modular design, ready to integrate next-gen PLMs for even better performance.
@idmjky @mat10_d @ssgriz @hnisimasu @lukas_villiger @alisankayabolen @omarabudayyeh @jgooten @MITdeptofBE
💻Code: github.com/mat10d/EvolvePro
📜Paper: science.org/doi/10.1126/scie…
#AI #ProteinEngineering #Bioinformatics #EVOLVEpro #DirectedEvolution #Therapeutics #CRISPR #RNA

Last Seen Hashtags on Sotwe
Most Popular Users

Elon Musk 
@elonmusk
240.3M followers

Barack Obama 
@barackobama
118.6M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
106.9M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.7M followers

KATY PERRY 
@katyperry
89.9M followers

Taylor Swift 
@taylorswift13
83.9M followers

Lady Gaga 
@ladygaga
75.4M followers

Virat Kohli 
@imvkohli
73.3M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.6M followers

Neymar Jr 
@neymarjr
66.3M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers


